ImmunoGen Stock Soars 80% on AbbVie’s $10 Billion Takeover

ImmunoGen stock was soaring Thursday following an

announcement

that biopharmaceutical company AbbVie has agreed to buy the cancer treatment developer for $10.1 billion.